VRAX
Virax Biolabs (VRAX)
NASDAQ
$4.01-$0.06 (-1.38%)
Price as of Jul 14, 2026 8:47 AM EDT
  • $417.1M
    Market Cap
  • -82.42%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
03/31/2026
03/31/2025
03/31/2024
03/31/2022
Income Statement
Total Operating Revenue
12,423
+96.22%
6,331
-95.95%
156,419
N/A
0
N/A
Cost of Revenue
4,733
-92.03%
59,398
-43.87%
105,829
-20.58%
133,254
N/A
Gross Profit
7,690
+114.49%
-53,067
-204.90%
50,590
+636.25%
-9,434
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
13,818
N/A
Research and Development Expense
-3.7M
+110.04%
-1.8M
+13.95%
-1.6M
+260.11%
-433,743
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
2.7M
-38.36%
4.3M
-5.76%
4.6M
+257.26%
1.3M
N/A
Operating Profit
-6.4M
+3.84%
-6.2M
-5.13%
-6.5M
+274.72%
-1.7M
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-5.0M
-17.06%
-6.1M
-9.97%
-6.7M
+285.12%
-1.7M
N/A
Income Taxes
-900,240
+558.74%
-136,661
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-5.0M
-17.06%
-6.1M
-9.97%
-6.7M
+285.12%
-1.7M
N/A
Net Income from Continuing Operations Applicable to Common
-5.0M
-17.06%
-6.1M
-9.97%
-6.7M
+285.12%
-1.7M
N/A
Basic EPS and Net Income
-12.64
+680.25%
-1.62
-51.79%
-3.36
+401.49%
-0.67
N/A
Diluted EPS and Net Income
-12.64
+680.25%
-1.62
-51.79%
-3.36
+401.49%
-0.67
N/A
Basic Weighted Average Shares
397,590
-89.34%
3.7M
+85.92%
2.0M
-21.34%
2.6M
N/A
Diluted Weighted Average Shares
397,590
-89.34%
3.7M
+85.92%
2.0M
-21.34%
2.6M
N/A
Balance Sheet
Cash and Cash Equivalents
6.4M
+52.26%
4.2M
+17.82%
3.6M
+16,397.72%
21,756
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
6.4M
+52.26%
4.2M
+17.82%
3.6M
+16,397.72%
21,756
N/A
Total Current Assets
6.8M
+39.54%
4.9M
+11.72%
4.4M
+8,893.25%
48,706
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
1.2M
-4.71%
1.2M
+36.65%
897,627
N/A
N/A
N/A
Total Long-Term Assets
1.5M
-2.42%
1.5M
+38.92%
1.1M
N/A
N/A
N/A
Total Assets
8.3M
+29.53%
6.4M
+17.19%
5.5M
+11,159.33%
48,706
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
685,024
+1.76%
673,207
+298.70%
168,849
-86.44%
1.2M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
989,832
+2.60%
964,750
+179.48%
345,194
-72.28%
1.2M
N/A
Retained Earnings
-29.6M
+20.43%
-24.6M
+32.71%
-18.5M
+192.38%
-6.3M
N/A
Total Stockholders Equity
7.3M
+34.29%
5.5M
+6.29%
5.1M
+529.41%
-1.2M
N/A
Total Shares Outstanding
579,218
-86.66%
4.3M
+68.69%
2.6M
-97.50%
103.0M
N/A
Cash Flow
Cash from Operating Activities
-4.6M
+1.28%
-4.6M
-26.95%
-6.2M
+672.12%
-809,069
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-255,831
-57.64%
-603,890
-48.14%
-1.2M
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
7.1M
+22.05%
5.8M
+252.34%
1.6M
+102.68%
813,205
N/A
Financials Ratio
Gross Margin
61.90%
+107.38%
-838.21%
N/A
N/A
N/A
N/A
N/A
Operating Margin
-51,515.17%
-47.08%
-97,344.76%
N/A
N/A
N/A
N/A
N/A
Return on Assets
-68.23%
-33.03%
-101.88%
N/A
N/A
N/A
N/A
N/A
Return on Equity
-78.65%
-31.29%
-114.47%
N/A
N/A
N/A
N/A
N/A
Revenue Growth
96.22%
+200.28%
-95.95%
N/A
N/A
N/A
N/A
N/A
Current Ratio
9.97
+37.13%
7.27
N/A
N/A
N/A
N/A
N/A
Cash Ratio
9.40
+49.63%
6.28
N/A
N/A
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow